Between 20- and 30-percent of patients with NORSE do not survive, and most survivors have lifelong epilepsy as well as significant neurological ... read more
In Small Case Series, Tocilizumab Shows Promise for New-Onset Refractory Status Epilepticus
In Small Case Series, Tocilizumab Shows Promise for New-Onset Refractory Status Epilepticus